A Phase I Study of CDX-622
← catalyst calendarSponsored by Celldex Therapeutics (industry) · CLDX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
85actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-01 | actual | When the study began enrolling |
| Primary completion | 2026-04-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-24 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: CDX-622
- Drug: Normal Saline
Primary outcome
what the primary-completion date above is the date OFSafety as assessed by Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Trials. Infusion reactions will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
measured Day 1 up to Day 127
Permalink · CLDX's whole pipeline · Catalyst calendar · Every registered study · What changed